Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection

Authors: Aylin Yilmaz, Åsa Mellgren, Dietmar Fuchs, Staffan Nilsson, Kaj Blennow, Henrik Zetterberg & Magnus Gisslén

Journal: Infectious Diseases

Year Published: 2019

Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low-level persistent immune activation in the central nervous system (CNS). There have been concerns regarding the CNS efficacy of tenofovir alafenamide fumarate (TAF) because of its […]

Back to Publications